Neoplasms

All Conditions

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Rare Diseases

Carcinoma

Sarcoma

Uterine Neoplasms

Carcinosarcoma

Mixed Tumor, Mullerian

Adenocarcinoma, Clear Cell

Sarcoma, Endometrial Stromal

Leiomyosarcoma

Adenomyoepithelioma

Endometrial Neoplasms

Adenocarcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Neoplasms, Connective and Soft Tissue

Genital Neoplasms, Female

Urogenital Neoplasms

Uterine Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Endometrial Stromal Tumors

Soft Tissue Sarcoma

Malignant Mixed Mullerian Tumor

Endometrial Stromal Sarcoma

Epithelial-myoepithelial Carcinoma

Embryonal Sarcoma

Antineoplastic Agents

All Drugs and Chemicals

Nivolumab

Antineoplastic Agents, Immunological

Immune Checkpoint Inhibitors

Nivolumab treatment: Nivolumab 480 mg IV once every 4 weeks. Treatment will continue until time of disease progression or until development of unacceptable toxicity, whichever comes first.

Claire Friedman, MD

The purpose of this study is to test the safety of nivolumab and find out what affects, if any, nivolumab has on people and their risk of gynecologic cancer. The investigators also want to find out what effects, good or bad, nivolumab has on the patient and their cancer.

This is an MSKCC investigator-initiated, single-center, non-randomized, open-label, phase 2 study.

A Study of Nivolumab in Selected Uterine Cancer Patients

Phase II Trial of Single-Agent Nivolumab in Patients With Microsatellite Unstable/Mismatch Repair Deficient/Hypermutated Uterine Cancer

will be evaluated in this study using the new international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1)

Bristol-Myers Squibb

Memorial Sloan Kettering Cancer Center

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
A Study of Nivolumab in Selected Uterine Cancer Patients	NCT03241745	Uterine Cancer Endometrial Car... Carcinosarcoma Leiomyosarcoma Undifferentiate... High Grade Endo... Clear Cell Carc...	Nivolumab	18 Years -	Memorial Sloan Kettering Cancer Center
A Study of Nivolumab in Selected Uterine Cancer Patients	NCT03241745	Uterine Cancer Endometrial Car... Carcinosarcoma Leiomyosarcoma Undifferentiate... High Grade Endo... Clear Cell Carc...	Nivolumab	18 Years -	Memorial Sloan Kettering Cancer Center

Spots Global Cancer Trial Database for high grade endometrial stromal sarcoma